Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-10-28 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2022年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "贝达药业股份有限公司 2022 年第三季度报告" which translates to "Betta Pharmaceuticals Co., Ltd. 2022 Third Quarter Report." It contains detailed financial data including income statements, balance sheets, cash flow statements, and explanations of financial metrics for the third quarter of 2022. The document includes comprehensive financial figures, management commentary on financial performance, shareholder information, and other disclosures typical of a quarterly financial report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is not a brief announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-28 Chinese
关于BPI-460372片药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the acceptance of a clinical trial application for a new drug (BPI-460372) by the National Medical Products Administration of China. It details the clinical trial application acceptance, drug research background, and potential impact and risks. The document is short (1230 characters) and serves as an official announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed financial data. It is not an annual or interim report, earnings release, or any other financial filing. It is a regulatory announcement about a clinical trial application acceptance, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2022-10-20 Chinese
关于股东部分股份质押延期购回的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the extension of a shareholder's stock pledge repayment period. It details the number of shares pledged, the proportion of shares involved, and the financial arrangements related to the pledge. There is no financial statement, earnings data, or management discussion of financial results. The document is an announcement about a shareholder's share pledge and related risk disclosures, which fits the category of Regulatory Filings (RNS) as it is a regulatory disclosure about share pledge status and risk, not a financial report or capital change announcement.
2022-10-17 Chinese
国浩律师（杭州）事务所关于贝达药业股份有限公司2022年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, agenda, voting process, and results of the 2022 second extraordinary general meeting (临时股东大会) of Betta Pharmaceuticals Co., Ltd. It details the legality and validity of the meeting and voting results, referencing relevant Chinese laws and regulations. The document is not a financial report, earnings release, or management discussion, but rather a legal opinion on the shareholder meeting and its resolutions. This type of document corresponds to the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and validates the shareholder meeting procedures and outcomes.
2022-10-17 Chinese
2022年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 second extraordinary general meeting (临时股东大会) of Betta Pharmaceuticals Co., Ltd. It includes voting results on multiple proposals related to a specific issuance of A shares, amendments to issuance plans, use of raised funds, election of directors, and other corporate governance matters. The document contains detailed voting statistics, mentions legal opinions on the meeting's validity, and confirms the resolutions were passed legally and effectively. This type of document is a formal declaration of voting results from a shareholders' meeting, not the meeting materials themselves or a general regulatory filing. It is not a full annual or interim report, nor a management discussion or earnings release. The focus on voting outcomes and resolutions aligns with the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length and detail confirm it is not a brief announcement or a simple report publication notice. Therefore, the correct classification is DVA with high confidence.
2022-10-17 Chinese
关于召开2022年第二次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2022 second extraordinary general meeting (临时股东大会) of the company 贝达药业股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), proposal details, registration instructions, and attachments such as proxy forms and voting instructions. The content focuses on informing shareholders about the meeting logistics and agenda items for voting, including proposals related to a specific share issuance and board member elections. There are no financial statements, earnings data, or management discussion and analysis sections present. The document is not a report of voting results but a notice or announcement about the meeting itself and how shareholders can participate and vote. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-10-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.